

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Yaron Ilan et al.

Serial No. 10/676,045

Filed: September 30, 2003

Title: **EDUCATED NKT CELLS AND THEIR USES
IN THE TREATMENT OF IMMUNE-RELATED
DISEASES**

Group Art Unit: 1644

Examiner: Zachary Skelding

527 Madison Avenue, 9th Floor
New York, NY 10022-4304
December 21, 2006


FILED VIA EXPRESS MAIL

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT OF JUNE 21, 2006

Dear Sirs:

In the Office Action of June 21, 2006, the Examiner requested restriction under 35 U.S.C. § 121 to one of Groups I-VIII, which are purportedly distinct inventions. Applicants hereby

| EXPRESS MAIL CERTIFICATE | |
|--|--------------------------|
| "Express Mail" Label No. | <u>EV655205455US</u> |
| Deposit Date | <u>December 21, 2006</u> |
| I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents and Trademarks, P.O. Box 1450, Alexandria, Virginia 22313-1450. | |
|  Natalie Bogdanos Reg. No. 52,480 | <u>12/21/06</u> Date |

provisionally elect Group II, which covers claims 3, 5-15, 19, 24 and 32, drawn to a method of treatment using NKT cells as an anti-inflammatory, classified in Class 424, subclass 93.21, according to the Office Action, with traverse. Applicants hereby provisionally elect Autoimmune Liver Disease as the specific immune-related or immune-mediated disorder, with traverse. Applicants also hereby provisionally elect antigens or epitopes as the set of culture conditions with traverse, and also elect “allogenic antigens obtained from donors suffering from said immune-related or immune-mediated disease”, with traverse. Applicants moreover reserve the right to file divisional applications directed to non-elected subject matter.